Employed by Investees
Co-investment and grants
We invest in innovative technologies.
We are a unique commercialisation fund helping researchers from our partner research organisations turn their ideas into products and services. We support innovations that solve market problems and create a positive impact for our community. Uniseed invests over a broad range of technology sectors and has exited six investments, to date.
How we help
Seed capital investment
We invest in your innovation to help you progress and de-risk from both a technical and commercial perspective.
We believe in supporting your progress through collaboration and mentoring.
You will have the ability to access Uniseed’s network of industry experts, co-investors and start-up experts.
We help you build your strategy, manage your intellectual property and identify commercial partners.
Rewards & recognition
Boost career profile, publications, conferences, patent publications and increase your visibility.
Make an impact
Impact our community by solving market problems through your innovation.
Our Process ›
Step 1: Make Contact
Get in contact through your commercialisation office or directly with us. Initial meetings and discussions will start with an Investment Manager. Tell us about your innovative opportunity and we will assist in identifying the most appropriate pathway forward.
Step 2: Pitch to Us
Promising eligible opportunities will have the opportunity to pitch to the Uniseed Investment Committees (which convenes monthly) and receive feedback.
Step 3: Due Diligence & Negotiation
Uniseed conducts detailed due diligence on your opportunity which may include further presentation(s) to our investment committee. We syndicate promising deals with your co-investors (as required)
Step 4: Investment & Growth
Investment capital is provided. Uniseed provides expert guidance and access to networks. We also help to develop, grow and scale your innovation.
Step 5: Impact & Exit
Generate impact through your innovation. Receive awards and recognition. Exit and achieve a return for shareholders.
Auris Medical Expands Clinical Development Pipeline with Intranasal Betahistine for the Treatment of Meniere’s Disease and Vestibular Vertigo – Pipeline strengthens with addition of AM-125 as third clinical-stage program – Acquisition of assets related to...read more
Uniseed makes £200,000 investment in Exonate as part of £1.5 million round from existing and new investors Exonate awarded £4.9 million from the Wellcome Trust ‐ Seeding Drug Discovery Initiative Program to develop eye drop treatment for wet age‐related macular...read more
Exonate receives Wellcome Trust funding to develop eye drop treatment for wet age-related macular degeneration (wet AMD) Early stage biotechnology company targeting ophthalmology and other areas of unmet medical need Cambridge, UK. Monday 6th February 2017 –...read more